Healthcare provider organizations spend over $40B annually on technology, yet most lack the structured intelligence and internal expertise needed to confidently evaluate an increasingly complex vendor landscape. With generative AI and advanced technologies creating a surge of healthcare solutions, providers face overwhelming arrays of high-stakes choices and time-consuming research that delays adoption and time-to-value. Elion addresses this critical gap by offering an AI-powered healthcare technology marketplace used by over 60% of U.S. health systems to evaluate and select vendors. The platform combines a structured dataset on thousands of healthcare technology products with deep expertise in health system workflows, helping provider organizations navigate complex procurement decisions with confidence and clarity. Elion has seen a 5x increase in usage over the past year, reflecting growing trust among health system decision-makers who rely on the platform’s vendor marketplace, research insights, and custom procurement support.
AlleyWatch sat down with Elion CEO and Cofounder Bobby Guelich to learn more about the business, its future plans, and recent funding round that brings total funding to $12.6M.
Who were your investors and how much did you raise?
Elion raised an oversubscribed $9.3M seed round led by existing investor NEA, with participation from new investors Cedars-Sinai Health Ventures, TMV, Scrub Capital, and Alumni Ventures, as well as continued support from Max Ventures, AlleyCorp, and Floating Point.
Tell us about the product or service that Elion offers.
Elion’s flagship product is an AI-powered healthcare technology marketplace used by over 60% of U.S. health systems to evaluate and select vendors. We combine a structured dataset on thousands of healthcare technology products with deep expertise in health system workflows, helping provider organizations navigate a complex and fast-changing digital health landscape. We also offer in-person events and consulting services to help healthcare providers make faster, higher-confidence vendor selection decisions.
What inspired the start of Elion?
At Oscar Health and Formation Bio, I was responsible for many high-stakes technology decisions, but the information I needed to make confident choices was almost never available. The landscape was fragmented, vendors were opaque, and credible intel on performance was nearly impossible to find. Crucially, the cost of a wrong decision was high, both for the business and for the people we served. We built Elion to make this process easier, more efficient, and data-informed for healthcare providers.
How is Elion different?
We focus exclusively on the provider market, mapping vendor intelligence to real-world workflows, procurement dynamics, and health system priorities. Our platform combines structured, continuously updated vendor data with accessible, decision-ready insights—going beyond simple directories or analyst reports.
What market does Elion target and how big is it?
We target the U.S. healthcare provider market, including health systems, hospitals, and large specialty practices—an ecosystem that spends over $40B annually on technology. Our traction with more than 60% of U.S. health systems underscores both the market need and the scale of the opportunity.
What’s your business model?
Access to our intelligence platform is completely free for both providers and vendors, allowing us to rapidly build one of the industry’s most robust vendor technology datasets. From there we offer deeper insights through targeted research, evaluation tools, and events that connect health system buyers and qualified vendors, which are paid offerings.
How are you preparing for a potential economic slowdown?
Healthcare procurement is already under intense budget scrutiny, which makes Elion’s role more critical. Our focus is on delivering measurable ROI to health systems by reducing the cost, time, and risk of technology decisions.
What was the funding process like?
We saw strong inbound interest from both strategic and financial investors. Our existing investors doubled down, and we added new strategic partners with deep healthcare expertise. The process was highly collaborative and focused on scaling responsibly to meet demand.
What are the biggest challenges that you faced while raising capital?
The challenge was not just demonstrating market potential, but proving that we could convert adoption into durable revenue. We addressed that by highlighting both our market penetration and the expanding ways customers are using Elion.
What factors about your business led your investors to write the check?
Investors were drawn to our unique market penetration and our ability to turn data into actionable decisions. They also saw strength in our team’s combination of healthcare and technology research experience.
What are the milestones you plan to achieve in the next six months?
We’ll expand our platform’s AI-driven evaluation capabilities, launch new research and benchmarking tools, and continue to host a series of AI Evaluation Accelerator Summits for health system leaders..
What advice can you offer companies in New York that do not have a fresh injection of capital in the bank?
Focus on deepening customer relationships and proving ROI. In healthcare, credibility and trust are currency—deliver consistently and make sure your value is visible.
Where do you see the company going now over the near term?
We’re doubling down on our role as the trusted intelligence platform for healthcare technology decisions, expanding both our product capabilities and our reach within the provider market.
What’s your favorite summer destination in and around the city?
I love Westerly, Rhode Island. Great beaches, great food, same distance from the city as the Hamptons, but much more chill.
You are seconds away from signing up for the hottest list in NYC Tech!
Sign up today
-1024x683.jpg "Judge Who Helped Violent Illegal Alien Evade ICE Faces New Test")
-1024x683.jpg "Montana Puts Democrats in a Bind as Senate Hopes Fade")
